A+ A A- Skip to main content

Asian Paints

2659.2 -27.50

Cipla

1387.9 -13.40

Eicher Motors

7050 -20.00

Nestle India

1398.9 12.70

Grasim Inds

3050.1 -37.60

Hindalco Inds.

1062.4 -30.20

Hind. Unilever

2110.1 -11.40

ITC

279.45 -1.25

Trent

2724.1 -50.10

Larsen & Toubro

3875.5 -77.70

M & M

2966 -74.50

Reliance Industries

1263.3 -27.70

Tata Consumer

1107 -23.90

Tata Motors PVeh

389 -8.80

Tata Steel

202.72 -4.05

Wipro

181.76 -16.61

Apollo Hospitals

8358.5 54.00

Dr Reddy's Labs

1275.6 -2.60

Titan Company

4192.4 -67.80

SBI

981.95 4.25

Shriram Finance

896.65 -26.65

Bharat Electron

412.95 4.75

Kotak Mah. Bank

377.1 -0.35

Infosys

1187.6 -9.90

Bajaj Finance

871.1 -18.30

Adani Enterp.

2970 -78.20

Sun Pharma.Inds.

1788.8 6.60

JSW Steel

1260.7 -23.30

HDFC Bank

738.65 -8.40

TCS

2151.4 -47.50

ICICI Bank

1250.2 -11.90

Power Grid Corpn

290.3 4.65

Maruti Suzuki

12912 -138.00

Axis Bank

1268.1 -4.20

HCL Technologies

1151.3 -3.40

O N G C

264.65 -0.10

NTPC

362.4 0.75

Coal India

464.9 -7.40

Bharti Airtel

1813.3 15.10

Tech Mahindra

1503.4 19.90

Jio Financial

228.86 -8.03

Adani Ports

1805 -19.20

HDFC Life Insur.

564.55 -10.75

SBI Life Insuran

1764.4 -18.40

Max Healthcare

1007.45 30.20

UltraTech Cem.

10795 -117.00

Bajaj Auto

10231 -111.00

Bajaj Finserv

1674.6 -28.60

Interglobe Aviat

4359.7 -121.60

Eternal

248.3 -8.20

Corporate News - Detailed News Back
Panacea Biotec announces launch of DENSTAR project
08-Jun-26   18:54 Hrs IST

Panacea Biotec announced the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll' in sub-Saharan Africa (sSA) and to facilitate its broader global use. The four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever, and seeks to reduce the disease burden across Africa.

The DENSTAR project is coordinated by the 'Sclavo Vaccines Association', a non-profit organization based in Siena (Italy) devoted to support vaccine research and development in developing countries. The DENSTAR consortium unites 10 Partners from 9 countries across Europe, Africa, the United States, India and South Korea which comprises of universities, research organizations, a biotech company and a non profit organization, bringing together experts, researchers, regulators, healthcare practitioners. Panacea Biotec being the developer of DengiAll', a tetravalent dengue vaccine targeting all four virus serotypes and currently in late-stage development in India, is a key partner of the DENSTAR consortium. This diverse and complementary consortium embodies a great public-private partnership, fully aligned with the DENSTAR project's goal to promote broader use of DengiAll' in Africa and globally, contributing to equitable access to safe and effective dengue prevention tools.


DJIA 51098.17
-484.76 -0.94%
S&P 500 7440.28
-165.03 -2.17%
HANG SENG 24657.07
-304.89 -1.22%
NIKKEI 225 63697.20
-2890.92 -4.34%
FTSE 100 10368.25
0.20 0.00%
NIFTY 23123.00
-243.70 -1.04%
×
Ask Your Question
close
refresh